Literature DB >> 1528356

Preferential inhibition of acetylcholinesterase molecular forms in rat brain.

N Ogane1, E Giacobini, E Messamore.   

Abstract

The effect of eight different acetylcholinesterase inhibitors (AChEIs) on the activity of acetylcholinesterase (AChE) molecular forms was investigated. Aqueous-soluble and detergent-soluble AChE molecular forms were separated from rat brain homogenate by sucrose density sedimentation. The bulk of soluble AChE corresponds to globular tetrameric (G4), and monomeric (G1) forms. Heptylphysostigmine (HEP) and diisopropylfluorophosphate were more selective for the G1 than for the G4 form in aqueous-soluble extract. Neostigmine showed slightly more selectivity for the G1 form both in aqueous- and detergent-soluble extracts. Other drugs such as physostigmine, echothiophate, BW284C51, tetrahydroaminoacridine, and metrifonate inhibited both aqueous- and detergent-soluble AChE molecular forms with similar potency. Inhibition of aqueous-soluble AChE by HEP was highly competitive with Triton X-100 in a gradient, indicating that HEP may bind to a detergent-sensitive non-catalytic site of AChE. These results suggest a differential sensitivity among AChE molecular forms to inhibition by drugs through an allosteric mechanism. The application of these properties in developing AChEIs for treatment of Alzheimer disease is considered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1528356     DOI: 10.1007/bf00969897

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

Review 1.  Present state and future development of the therapy of Alzheimer disease.

Authors:  M Pomponi; E Giacobini; M Brufani
Journal:  Aging (Milano)       Date:  1990-06

2.  In vivo and in vitro effects of diisopropyl fluorophosphate and paraoxon on individual molecular forms of rat brain acetylcholinesterase.

Authors:  M T Volpe; G M Bisso; H Michalek
Journal:  Neurochem Res       Date:  1990-10       Impact factor: 3.996

3.  Solubilization and physicochemical characterization of rat brain acetylcholinesterase: development and maturation of its molecular forms.

Authors:  F Rieger; M Vigny
Journal:  J Neurochem       Date:  1976-07       Impact factor: 5.372

4.  Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia.

Authors:  M Brufani; M Marta; M Pomponi
Journal:  Eur J Biochem       Date:  1986-05-15

5.  Responses of acetylcholinesterase from Torpedo marmorata to salts and curarizing drugs.

Authors:  J P Changeux
Journal:  Mol Pharmacol       Date:  1966-09       Impact factor: 4.436

6.  Are soluble and membrane-bound rat brain acetylcholinesterase different?

Authors:  C Andres; M el Mourabit; C Stutz; J Mark; A Waksman
Journal:  Neurochem Res       Date:  1990-11       Impact factor: 3.996

7.  Acetylcholinesterase activity in cerebrospinal fluid of patients with Alzheimer's disease and senile dementia.

Authors:  S Nakano; T Kato; S Nakamura; M Kameyama
Journal:  J Neurol Sci       Date:  1986-09       Impact factor: 3.181

8.  Acetylcholinesterase from bovine caudate nucleus is attached to membranes by a novel subunit distinct from those of acetylcholinesterases in other tissues.

Authors:  N C Inestrosa; W L Roberts; T L Marshall; T L Rosenberry
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

9.  Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain.

Authors:  G C Siek; L S Katz; E B Fishman; T S Korosi; J K Marquis
Journal:  Biol Psychiatry       Date:  1990-03-15       Impact factor: 13.382

10.  Cellular localization of the molecular forms of acetylcholinesterase in rat pheochromocytoma PC12 cells treated with nerve growth factor.

Authors:  N C Inestrosa; C G Reiness; L F Reichardt; Z W Hall
Journal:  J Neurosci       Date:  1981-11       Impact factor: 6.167

View more
  7 in total

Review 1.  Metrifonate.

Authors:  H M Lamb; D Faulds
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 2.  Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

Authors:  E Giacobini
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Effects per se of organic solvents in the cerebral acetylcholinesterase of rats.

Authors:  Adriana D C Obregon; Maria R C Schetinger; Maísa M Correa; Vera M Morsch; José E P da Silva; Marcos A P Martins; Hélio G Bonacorso; Nilo Zanatta
Journal:  Neurochem Res       Date:  2005-03       Impact factor: 3.996

4.  Differential inhibition of soluble and membrane-bound acetylcholinesterase forms from mouse brain by choline esters with an acyl moiety of an intermediate size.

Authors:  Y Cho; S H Cha; D E Sok
Journal:  Neurochem Res       Date:  1994-07       Impact factor: 3.996

5.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

6.  Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid.

Authors:  María-Salud García-Ayllón; David H Small; Jesús Avila; Javier Sáez-Valero
Journal:  Front Mol Neurosci       Date:  2011-09-13       Impact factor: 5.639

7.  Brain cholinergic impairment in liver failure.

Authors:  María-Salud García-Ayllón; Omar Cauli; María-Ximena Silveyra; Regina Rodrigo; Asunción Candela; Antonio Compañ; Rodrigo Jover; Miguel Pérez-Mateo; Salvador Martínez; Vicente Felipo; Javier Sáez-Valero
Journal:  Brain       Date:  2008-09-04       Impact factor: 13.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.